This Week’s Biotech Highlights
This week saw an unusually large amount of biotech deal activity in Canada, so you should check out the Monday Deal Review for all those details; but in between all the transactions, there were some interesting concepts to think about:
REMS: The FDA has, increasingly often, been imposing Risk Evaluation and Mitigation Strategies when it approves new drugs. REMS restrict the way new drugs can be distributed, administered and/or promoted. When the program was first introduced, common wisdom said that REMS were to be avoided at all costs, but lately some advantages have become apparent:
- Way back in June, we
